AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00854828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-operative intervention
Description: Non operative intervention as appropriate for treatment of adults with symptomatic lumbar scoliosis such as: injections, medications, physical therapy, etc.
Study NCT03260569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Nitric Oxide
Description: Patients randomized to this arm will receive inhaled nitric oxide 20 parts per million.
Study NCT03260569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nitrogen plus oxygen
Study NCT01704079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTAP101 30 μg capsules
Description: CTAP101 30 μg capsule taken daily at bedtime
Study NCT01704079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar pill to CTAP101 30 μg capsules
Description: Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
Study NCT01704079 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill to CTAP101 30 μg capsules
Description: Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
Study NCT01314118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate in combination with prednisone
Description: Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.
Study NCT02181166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy
Study NCT04583722 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: AX-olive oil-PP emulsion
Description: single dose and plasma samples
Study NCT04583722 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AX-olive oil-PP emulsion
Description: single dose and plasma samples
Study NCT02992197 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix, dose 1
Description: Rotarix, dose 1
Study NCT02992197 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix, dose 1
Description: Rotarix, dose 1
Study NCT02992197 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix, dose 2
Description: Rotarix, dose 2
Study NCT02992197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Rotarix dose 2)
Description: Sterile water to provide volume equivalent as a second dose of Rotarix
Study NCT02181166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isquemic compression
Study NCT02181166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High voltage electrical stimulation
Study NCT04133961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine infusion 0.3ml/kg/hour (equivalent to 0.5mcg/kg/min, phenylephrine dilution is 100mcg/ml in 20ml syringe)
Study NCT04133961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline infusion 0.3ml/kg/hour (normal saline in 20ml syringe)
Study NCT02426177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: anti-hypertensive agents
Study NCT02426177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: calcium channel blocker ,for lowering blood pressure
Study NCT01213212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Description: Caloric restriction.
Study NCT01213212 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervention
Description: Diet ad libitum
Study NCT03742037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod 0.5 mg
Description: Cenerimod will be supplied as a film-coated tablets at the dose of 0.5 mg
Study NCT03742037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod 1 mg
Description: Cenerimod will be supplied as a film-coated tablets at the dose of 1 mg
Study NCT03742037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod 2 mg
Description: Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg
Study NCT03742037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod 4 mg
Description: Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg
Study NCT03742037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod
Study NCT03742037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cenerimod 2 mg (ex-4 mg)
Description: Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg
Study NCT04001868 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suboccipital inhibition
Description: With the patient in the supine position and the therapist sitting at the head of the bed with the elbows resting on its surface. The therapist palpates the cervical spinous processes and slides the fingers upwards until contacting the posterior projection of the posterior arch of the atlas. Then, flexing the metacarpophalangeal at 90 degrees slowly raises the skull. The therapist's hands should remain together and the base of the skull should rest on his palms pressing with the index, middle and ring fingers of each hand in a sustained manner, but without causing pain. This pressure must be maintained during 4 minutes.
Study NCT04001868 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo technique
Description: A superficial contact in the same area as the intervention, to rule out the exteroceptive effect associated with the therapist's contact.
Study NCT02260518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: During pregnancy, participants complete one face-to-face counseling session, receive 10 behavioral podcasts, and receive weekly phone calls until delivery. Participants will be asked to attend one group session on breastfeeding. Participants will have the opportunity to participate in a private Facebook group during pregnancy and postpartum. During postpartum, participants complete one face-to-face counseling session, receive 16 behavioral podcasts, receive brief weekly check-in telephone calls for six weeks, and receive up to 8 telephone counseling calls through 6 months after delivery.
Study NCT02260518 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Women will receive standard nutrition counseling provided by physicians, nurses, nutritionists, and counselors from the Women, Infants, and Children (WIC) program (if applicable). They will receive a monthly study mailing that is educational in nature as well as podcasts related to a healthy pregnancy. During pregnancy, the mailings will focus on tips for a healthy pregnancy and on fetal development. During postpartum the mailings will focus on infant development and parenting. We will select a matched number of podcasts from Pea in the Podcast, commercially available podcasts. All mailings and podcasts will avoid discussion of weight, PA, or diet (except for foods to avoid in pregnancy for safety reasons).
Study NCT03485209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tisotumab vedotin
Description: Given into the vein (IV; intravenously)
Study NCT03485209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200mg or 400mg given by IV
Study NCT01738477 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: Single dose intramuscular administration.
Study NCT01738477 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix
Description: Single dose intramuscular administration.
Study NCT03485209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 5mg/mL per minute or AUC 3.3mg/mL per minute given by IV
Study NCT03485209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 100mg/m\^2 given by IV
Study NCT00134628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: HBO at 2.0 ATA
Study NCT00134628 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Normal air under pressure (1.1 ATA)
Study NCT03341169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N(2)-L-Alanine L-Glutamine dipeptide
Description: :Intravenous infusion of N (2) -L-alanyl-L-glutamine(mixed with normal saline, ratio 1:1) at the dose of 0.25g/kg(body weight) for 8 hours before induction of anesthesia(rate=2.5\*weight/8 ml/h) and administration another 0.25g/kg(body weight) of N (2) -L-alanyl-L-glutamine(mixed with 8.5% amino acid solution, ratio 1:5) into the central vein for 10 hours after induction of anesthesia(rate=0.75\*weight ml/h)
Study NCT03341169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (0.9% NaCl (normal saline))
Description: Intravenous infusion of 0.9% NaCl for 8 hours before induction of anesthesia(rate=2.5\*weight/8 ml/h) and administration 0.9% NaCl into the central vein for 10 hours after induction of anesthesia(rate=0.75\*weight ml/h)
Study NCT01805947 — intervention group
Intervention type: BEHAVIORAL
Intervention: Lifestyle Modification
Description: Lifestyle Modification
Study NCT00742469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Study NCT00742469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02864472 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: PDT
Description: PDT and ranibizumab
Study NCT02864472 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab
Description: Ranibizumab
Study NCT02864472 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ranibizumab PRN
Description: ranibizumab PRN
Study NCT01015833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00578760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: 325mg ASA OD for the duration of the cisplatin
Study NCT00578760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: OD for course of cisplatin chemotherapy
Study NCT02562235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: For children with body-weight \<50 kg at screening: body-weight adjusted dose equivalent to the exposure of (0.5 mg) 1.0 - 2.5 mg three times a day, IDT in adults treated for PAH; oral suspension. For children ≥50 kg at screening: 1.0 to 2.5 mg three times a day; oral tablet.
Study NCT02759744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound image-guided ablation device
Description: ultrasound image-guided focal ablation - may be either laser ablation or cryotherapy
Study NCT01015833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01015833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies
Study NCT01015833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT02622945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS plus Speech-Language Therapy
Description: Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain not affected by the lesion(perilesional areas, right hemisphere or cerebellum). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
Study NCT00954109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: daily exercise: supervised treadmill walking or cycle ergometry use
Study NCT01419431 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic resection
Description: Inflammatory response in laparoscopic surgery
Study NCT03663088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GPR-A
Description: Standard Global postural re-education physiotherapy scoliosis specific exercises
Study NCT03663088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GPR-B
Description: Experimental Global postural re-education physiotherapy scoliosis specific exercises combining individual and class exercises
Study NCT02622945 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham plus Speech-Language Therapy
Description: Speech-Language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
Study NCT00486837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha1-Proteinase Inhibitor (Human)
Description: 25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.
Study NCT03104101 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: TPTNS+Drug
Description: one tablet Trospium Chloride 20 mg once daily Plus TPTNS
Study NCT04360382 — intervention group
Intervention type: OTHER
Intervention: ERACS
Description: Pregnant women scheduled for cesarean section will be subjected to preoperative, intra-operative and postoperative nurse care aiming at early recovery.
Study NCT04360382 — intervention group
Intervention type: OTHER
Intervention: Regular care
Description: Usual care for all cases subjected to cesarean section at our hospital.
Study NCT02365480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine Chloride
Description: Given PO
Study NCT03104101 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TPTNS
Description: Surface adhesive electrodes placed on the skin above medial malleolus
Study NCT02365480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02365480 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02365480 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT03238014 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation
Description: Noninvasive positive pressure ventilation used assist/control mode treat severe stable chronic obstructive pulmonary disease.
Study NCT03238014 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive positive pressure ventilation
Description: Noninvasive positive pressure ventilation used assist/control mode treat severe stable chronic obstructive pulmonary disease.
Study NCT02055638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRX246
Description: capsules
Study NCT02055638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00815555 — intervention group
Intervention type: OTHER
Intervention: There is no intervention - this is an observational study
Study NCT03817086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand coordination and mental practice
Description: 20 chronic (>1year) moderate to severe TBI patients, with upper extremity movement deficits, will be randomly and equally assigned to two groups.~In the experimental group, participants undergo 5 weeks (3 hrs/week) of physical practice training combined with mental practice (MP group).
Study NCT03817086 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand coordination and action observation
Description: In the control group 2, participants undergo 5 weeks (3 hrs/week) of physical training (PP group).
Study NCT03692819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session.
Study NCT03692819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 Mg
Description: Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session after the therapy will be administered the antibiotic (Metronidazole 400mg + Amoxicillin 500mg) every 8 hours for 7 days
Study NCT01988090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 800 IU Vitamin D Supplement
Description: Standard Dose
Study NCT01988090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50,000 IU Vitamin D supplement
Description: High Dose
Study NCT04659421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combined therapy with rh-ES and CV
Description: All the patients receive combined therapy with recombinant human endostatin and traditional weekly CV regimen.~Carboplatin is administered at a dose of 220 mg/m2. Vincristine is administered at a dose of 1.5 mg/m2 (maximum dose 2 mg). Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks.
Study NCT01206153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Study NCT02102425 — intervention group
Intervention type: PROCEDURE
Intervention: Patients with or without bandage over exit site
Study NCT00017953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The lifestyle intervention is implemented with individual supervision and group sessions and is aimed at achieving and maintaining at least a 7% decrease in weight from baseline and 175 minutes per week in physical activity. It is implemented during a four-year period with the most intensive application during the first year, less frequent attention during the next three years, and a minimum of twice yearly contacts during an extended follow-up period. To help participants achieve and maintain weight loss, a variety of diet strategies (e.g. prepared meals and liquid formula), exercise strategies, and optional weight loss medications are utilized based on a preset algorithm and participant progress.
Study NCT00017953 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Support and Education
Description: Participants assigned to diabetes support and education are offered three sessions each year in diabetes management and social support.
Study NCT00936871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine
Description: Lersivirine 2400 mg single dose
Study NCT00936871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo single dose
Study NCT00936871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine (if necessary)
Description: Lersivirine 2100 mg single dose (if necessary)
Study NCT00936871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine
Description: Lersivirine 2400 mg single dose (dose may be decreased pending Part A tolerability results)
Study NCT00936871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg single dose
Study NCT02770963 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Shenshu (BL23) on bilateral sides and Dachangshu (BL25), Weizhong (BL40), and Chengshan (BL57) on the affected side will be applied.~A Huatuo Brand needle (0.3\*75 mm) for BL25 will be inserted at a depth of 40-70 mm vertically until the patient feels soreness and a distension sensation that radiates to the leg. The needle will be lifted 1-2 mm without rotating or lifting. Huatuo Brand needles (0.3\*40 mm) at the other acupoints (BL23, BL40 and BL57) will be inserted 30 mm and manipulated by lifting, thrusting, twirling evenly until the Deqi sensation is achieved. The needles in these acupoints will be manipulated by small evenly applied lifting, thrusting, and twirling movements 3 times every 10 minutes.
Study NCT02770963 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Specially designed sham needles (0.3\*25 mm) will be used. The sham needle consists of a needle handle, needle body, blunt tip and a sterile polyethylene cylindrical foam pad (identical to the pads in the acupuncture group).~The acupoints will be the same as the acupuncture group. The needle will be inserted vertically until pressed against the skin without penetration. The manipulation will be consistent with the acupuncture group and blind to the patients.
Study NCT02545153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tisseel, Baxter (Aprotinin and Fibrinogen)
Description: After introducton of t tube and closure of the incision with running sutures, fibrin sealant is applied on the incision.
Study NCT02545153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No fibrin sealant applied
Study NCT02589964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Florajen-3
Description: The probiotic treatment is the experimental aspect of the study. Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days.
Study NCT02589964 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo treatment is the experimental aspect of the study. Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days.
Study NCT01914497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acutus Medical System Mapping